07195nam 2202149z- 450 991055712910332120240124162354.0(CKB)5400000000040763(oapen)https://directory.doabooks.org/handle/20.500.12854/68429(EXLCZ)99540000000004076320202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer AgentsDesign, Synthesis and EvaluationBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (606 p.)3-0365-0140-1 3-0365-0141-X This book is a printed edition of the Special Issue entitled “Anticancer Agents: Design, Synthesis and Evaluation” that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers.Anticancer AgentsMedicinebicsscbenzofuranschemical synthesiscytotoxic propertiesHeLaMOLT-4K562anticanceranti-neuroinflammationcoumarindihydroartemisininflavonoidsalleneE-stereoselectiveregioselectiveanti-cancer activitycyanopyridonesubstituted pyridinepyridotriazinepyrazolopyridinethioxotriazopyridineanticancer activityHepG2antitumor activitycomputational dockingMDM2-p53 interactionxanthonesyeast-based assaysestrone derivativeshydrazineN-substituted pyrazolineanti-ovarian cancertopoisomerase II inhibitorkinase inhibitorantiproliferative agentureasynthesisantiproliferative activityapoptosisindoleamine 2,3-dioxygenaseinhibitoranti-tumorimmune modulationtryptophan metabolismtaxoidsβIII-tubulinP-glycoproteindrug resistancethiopenethienopyrimidinonethiazolidinonebreast cancerbenzofuran–pyrazolenanoparticlescytotoxic activityPARP-1 inhibition3,6-dibromocarbazole5-bromoindolecarbazoleactinmigrationThienopyrimidinePyrazolePI3Kα inhibitorquinazolin-4(3H)-onequinazolin-4(3H)-thioneSchiff baseantioxidant activityDFT studyortho-quinonesbeta-lapachonetanshione IIAPI3KsPI3Kδ inhibitors2H-benzo[e][1,2,4]thiadiazine 1,1-dioxideanticancer agentsprotein–protein interactionsvirtual screeningmimeticsdrug discoverybivalencypolyvalencyantitumorcell cycleovarian cancerP-MAPAIL-12TLR signalinginflammationchemoresistance4-(pyridin-4-yloxy)benzamide1,2,3-triazolec-Metnatural productanticancer agentzampanolideTalazoparibPARP inhibitorprodrugo-nitro-benzylphotoactivatable protecting groupssalinomycinovercoming drug resistancetumor specificitysynergy5-fluorouracilgemcitabineamides/esterscolchicine analogsthiocolchicinecolchiceineantimitotic agentshydratesdihydropyranoindoleHDAC inhibitorsneuroblastomaaromataseMCF-7NIH3T3benzimidazoletriazolothiadiazinedockingADMEorganosilicon compoundsSILA-409 (Alis-409)SILA-421 (Alis-421)multidrug resistance (MDR) reversalABCB1 (P-glycoprotein)colon cancercolchicine amidecolchicine sulfonamidetubulin inhibitorsdocking studiescrystal structurePROTACsprotein degradationIGF-1RSrcprotein kinasephenylpyrazolopyrimidineenzyme inhibitionmolecular simulationandrogen receptorprostate cancerenzalutamideapalutamidedarolutamidetriple-negative breast cancercytotoxicitychrysin analoguesflavonoidanticancer compoundsMedicineChen Qiao-Hongedt1313308Chen Qiao-HongothBOOK9910557129103321Anticancer Agents3031264UNINA